epirubicin has been researched along with Jaundice, Cholestatic in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Boettge, KR; De Santo, G; Paasch, C; Strik, MW | 1 |
Chen, Y; Cheng, JM; Gong, GQ; Liu, QX; Liu, R; Luo, JJ; Qian, S; Wang, JH; Wang, XL; Yan, ZP | 1 |
2 other study(ies) available for epirubicin and Jaundice, Cholestatic
Article | Year |
---|---|
Mesenchymal chondrosarcoma metastasising to the pancreas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adjuvant; Cholangiopancreatography, Endoscopic Retrograde; Chondrosarcoma, Mesenchymal; Common Bile Duct; Epirubicin; Humans; Ifosfamide; Ilium; Jaundice, Obstructive; Laminectomy; Magnetic Resonance Imaging; Male; Middle Aged; Palliative Care; Pancreatic Neoplasms; Radiotherapy, Adjuvant; Ribs; Sacrum; Spinal Fusion; Spinal Neoplasms; Thoracic Vertebrae; Tomography, X-Ray Computed | 2018 |
[Epirubicin in the treatment of malignant obstructive jaundice].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Bile Duct Neoplasms; Bilirubin; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Epirubicin; Female; Follow-Up Studies; Humans; Iodized Oil; Jaundice, Obstructive; Liver Neoplasms; Male; Middle Aged; Recurrence; Survival Rate | 2006 |